PEAK6’s ARK Genomic Revolution ETF ARKG Stock Holding History

PEAK6’s Portfolio ARKG Stock Details ARKG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-94,900	Closed	-$2.75M	–	2683
2025 Q4	$2.75M	Sell	94,900 -27,100	-22%	-$813K	0.01%	1259
2025 Q3	$3.39M	Buy	+122,000	New	+$3.08M	0.01%	1221

Other funds holding ARKG

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

State of Wisconsin Investment Board Madison, Wisconsin $43.7B AUM 27.76% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

PEAK6's ARKG Position: Q4 2025 in Review

PEAK6 sold out of ARK Genomic Revolution ETF (ARKG) in Q4 2025, closing a stake of 2,500 shares — an estimated $75K sold.

PEAK6 first reported a position in ARKG in Q3 2025 and held it in 1 quarter. The position peaked at $69.4K in Q3 2025. 238 funds tracked by Wall St. Rank hold ARKG as of Q4 2025.

PEAK6 reported no remaining ARK Genomic Revolution ETF position as of Q4 2025 after selling out during the quarter.
PEAK6 sold 2,500 ARK Genomic Revolution ETF shares in Q4 2025, an estimated $75K.
PEAK6 first reported a position in ARK Genomic Revolution ETF in Q3 2025 and held it in 1 quarter.
PEAK6's ARK Genomic Revolution ETF position peaked at $69.4K in Q3 2025.
238 funds tracked by Wall St. Rank held ARK Genomic Revolution ETF as of Q4 2025.

Based on PEAK6's 13F filing for Q4 2025, filed 13 Feb 2026.